Literature DB >> 32990768

Beyond abstinence and relapse: cluster analysis of drug-use patterns during treatment as an outcome measure for clinical trials.

Leigh V Panlilio1, Samuel W Stull2, Jeremiah W Bertz2, Albert J Burgess-Hull2, William J Kowalczyk2,3, Karran A Phillips2, David H Epstein2, Kenzie L Preston2.   

Abstract

RATIONALE: Many people being treated for opioid use disorder continue to use drugs during treatment. This use occurs in patterns that rarely conform to well-defined cycles of abstinence and relapse. Systematic identification and evaluation of these patterns could enhance analysis of clinical trials and provide insight into drug use.
OBJECTIVES: To evaluate such an approach, we analyzed patterns of opioid and cocaine use from three randomized clinical trials of contingency management in methadone-treated participants.
METHODS: Sequences of drug test results were analyzed with unsupervised machine-learning techniques, including hierarchical clustering of categorical results (i.e., whether any samples were positive during each week) and K-means longitudinal clustering of quantitative results (i.e., the proportion positive each week). The sensitivity of cluster membership as an experimental outcome was assessed based on the effects of contingency management. External validation of clusters was based on drug craving and other symptoms of substance use disorder.
RESULTS: In each clinical trial, we identified four clusters of use patterns, which can be described as opioid use, cocaine use, dual use (opioid and cocaine), and partial/complete abstinence. Different clustering techniques produced substantially similar classifications of individual participants, with strong above-chance agreement. Contingency management increased membership in clusters with lower levels of drug use and fewer symptoms of substance use disorder.
CONCLUSIONS: Cluster analysis provides person-level output that is more interpretable and actionable than traditional outcome measures, providing a concrete answer to the question of what clinicians can tell patients about the success rates of new treatments.

Entities:  

Keywords:  Cluster analysis; Cocaine; Contingency management; Methadone; Opioids; Substance use disorder; Treatment outcomes

Year:  2020        PMID: 32990768      PMCID: PMC7579498          DOI: 10.1007/s00213-020-05618-5

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  43 in total

Review 1.  Maintenance medication for opiate addiction: the foundation of recovery.

Authors:  Gavin Bart
Journal:  J Addict Dis       Date:  2012

Review 2.  Science-Based Actions Can Help Address the Opioid Crisis.

Authors:  David H Epstein; Markus Heilig; Yavin Shaham
Journal:  Trends Pharmacol Sci       Date:  2018-11       Impact factor: 14.819

3.  Trajectories of injection drug use among people who use drugs in Vancouver, Canada, 1996-2017: growth mixture modeling using data from prospective cohort studies.

Authors:  Huiru Dong; Kanna Hayashi; Joel Singer; Michael John Milloy; Kora DeBeck; Evan Wood; Thomas Kerr
Journal:  Addiction       Date:  2019-08-16       Impact factor: 6.526

4.  Contrasting trajectories of heroin, cocaine, and methamphetamine use.

Authors:  Yih-Ing Hser; David Huang; Mary-Lynn Brecht; Libo Li; Elizabeth Evans
Journal:  J Addict Dis       Date:  2008

5.  Non-treatment laboratory stress- and cue-reactivity studies are associated with decreased substance use among drug-dependent individuals.

Authors:  Stacia M DeSantis; Dipankar Bandyopadhyay; Sudie E Back; Kathleen T Brady
Journal:  Drug Alcohol Depend       Date:  2009-08-29       Impact factor: 4.492

6.  Temporal patterns of heroin and cocaine use among methadone patients.

Authors:  S Magura; S Y Kang; P C Nwakeze; S Demsky
Journal:  Subst Use Misuse       Date:  1998-10       Impact factor: 2.164

7.  Promoting abstinence from cocaine and heroin with a methadone dose increase and a novel contingency.

Authors:  David H Epstein; John Schmittner; Annie Umbricht; Jennifer R Schroeder; Eric T Moolchan; Kenzie L Preston
Journal:  Drug Alcohol Depend       Date:  2008-12-19       Impact factor: 4.492

Review 8.  Pharmacotherapy of Opioid Addiction: "Putting a Real Face on a False Demon".

Authors:  E Salsitz; T Wiegand
Journal:  J Med Toxicol       Date:  2016-03

9.  Analysis of self-report and biochemically verified tobacco abstinence outcomes with missing data: a sensitivity analysis using two-stage imputation.

Authors:  Yiwen Zhang; Xianghua Luo; Chap T Le; Jasjit S Ahluwalia; Janet L Thomas
Journal:  BMC Med Res Methodol       Date:  2018-12-18       Impact factor: 4.615

10.  Measurement-based care using DSM-5 for opioid use disorder: can we make opioid medication treatment more effective?

Authors:  John Marsden; Betty Tai; Robert Ali; Lian Hu; A John Rush; Nora Volkow
Journal:  Addiction       Date:  2019-01-30       Impact factor: 6.526

View more
  3 in total

1.  Lack of effect of different pain-related manipulations on opioid self-administration, reinstatement of opioid seeking, and opioid choice in rats.

Authors:  David J Reiner; E Andrew Townsend; Javier Orihuel; Sarah V Applebey; Sarah M Claypool; Matthew L Banks; Yavin Shaham; S Stevens Negus
Journal:  Psychopharmacology (Berl)       Date:  2021-03-25       Impact factor: 4.530

2.  Characterizing cannabis use reduction and change in functioning during treatment: Initial steps on the path to new clinical endpoints.

Authors:  Jacob T Borodovsky; Michael J Sofis; Brian J Sherman; Kevin M Gray; Alan J Budney
Journal:  Psychol Addict Behav       Date:  2022-01-27

3.  Beyond abstinence and relapse II: momentary relationships between stress, craving, and lapse within clusters of patients with similar patterns of drug use.

Authors:  Leigh V Panlilio; Samuel W Stull; Jeremiah W Bertz; Albert J Burgess-Hull; Stephanie T Lanza; Brenda L Curtis; Karran A Phillips; David H Epstein; Kenzie L Preston
Journal:  Psychopharmacology (Berl)       Date:  2021-02-08       Impact factor: 4.415

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.